Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: The danish endometrial cancer study

International Journal of Gynecological Cancer

Volumn 23, Issue 8, 2013, Pages 1429-1437

  Ørtoft, Gitte ^a   Hansen, Estrid Stæhr ^a   Bertelsen, Kamma ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

DEMCA; Endometrial cancer; Intermediate risk; Low risk; Radiotherapy; Recurrence rates; Salvage of recurrences

Indexed keywords

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGE; ARTICLE; BODY MASS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HYSTERECTOMY; LOCAL RECURRENCE FREE SURVIVAL; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PATIENT DECISION MAKING; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SURVIVAL RATE; UTERUS CARCINOMA;

AGED; AGED, 80 AND OVER; DENMARK; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT;

EID: 84888259912     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182a5e77d     Document Type: Article

References (24)

1. Amant F, Mirza MR, Creutzberg CL. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2012;119:s110-s117.
2. Chan JK, Kapp DS. Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol. 2007;8:831-841.
3. The writing committee on behalf of the ASTEC Study Group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125-136.
4. Seracchioli R, Solfrini S, Mabrouk M, et al. Controversies in surgical staging of endometrial cancer. Obstet Gynecol Int. 2010;18:1963.
5. Alders J, Abeler J, Kolstad P, et al. Postoperative external irradiation and prognosis parameters in stage I endometrial carcinoma: clinical and histopathogenic study of 540 patients. Obstet Gynecol. 1980;56:419-426.
6. Creutzberg CL, Van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial-PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355:1404-1411.
7. The ASTEC/EN.5 writing committee on behalf of the ASTEC/ EN.5 Study Group. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373:137-146.
8. Bertelsen K, Ortoft G, Hansen ES. Survival of Danish patients with endometrial cancer in the intermediate-risk group not given postoperative radiotherapy. Int J Gynecol Cancer. 2011;21:1191-1199.
9. Poulsen HK, Jacobsen M, Bertelsen K, et al. Patients with early stages of endometrial cancer should be spared adjuvant radiotherapy. Danish Endometrial Cancer Group. Int J Gynecol Cancer. 1996;6:38-43.
10. Hogberg T, Rosenberg P, Kristensen G, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) T chemotherapy (CT) in early-stage high-risk endometrial cancer (NSOG-EC-9501/Eortec 55991). J Clin Oncol. 2007;25:5503.
11. Hogberg T. What is the role of chemotherapy in endometrial cancer? Curr Oncol Rep. 2011;13:433-441.
12. Johnson N, Bryant A, Miles T, et al. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev. 2011;5:CD003175.
13. Randall ME, Filiaci V, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24:36-44.
14. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95:105-143.
15. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744-751.
16. Stata Statistical Software, Release 9.0 Collage Station, USA; 2005.
17. Creutzberg CL, van Putten WLJ, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89:201-209.
18. Creutzberg CL, Nout RA, Lybeert ML, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;15:e631-e638.
19. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev. 2012;18:CD003916.
20. Neut RA, van de Poll-Franse LW, Lybeert MLM, et al. Long-term outcome and quality of life of patientswith endometrial carcinoma treated with or without pelvic radiotherapy in post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol. 2011;29:1692-1700.
21. Owen P, Duncan ID. Is there any value in the long termfollow up of women treated for endometrial cancer? Br J Obstet Gynaecol. 1996;103:710-713.
22. Salvesen HB, Akslen LA, Iversen T, et al. Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol. 1997;104:1302-1307.
23. Agboola OO, Grunfeld E, Coyle D, et al. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. CMAJ. 1997;157:879-886.
24. Ueda Y, Enomoto T, Takata TE, et al. Endometrial carcinoma: better prognosis for asymptomatic recurrences than for symptomatic cases found by routine follow-up. Int J Clin Oncol. 2010;15:406-412.